← Back to signals
BSX
BUYBoston Scientific Corporation
Health Care
0.80
PEGY ratio
Rank #116
Why This Matters
This stock appears undervalued relative to its growth and dividend yield. Strong projected growth of 56.3% annually over 5 years.
BSX trades at 20.1x earnings against 25.0% capped growth (actual 56.3%) (no dividend) (PEGY 0.80). Valuation looks favorable — the price is not fully reflecting the growth and yield on offer.
~ Growth estimate uses historical CAGR (forward estimates unavailable)
- • Growth rate derived from historical CAGR — limited analyst coverage.
- • Growth rate capped at 25% for PEGY calculation (actual: 56.3%). Per Peter Lynch methodology, growth above 25% is rarely sustainable over 5 years.
Scan date: 2026-06-02
Valuation
20.1x
P/E Ratio
Growth
56.3%
5yr EPS
Income
0.0%
Div Yield
PEGY Components
PEGY Score0.80
Denominator25.0%
EPS (TTM)$2.39
Market Data
Price$47.98
ExchangeNYSE
S&P 500
What Changed
PEGY Score
0.97→0.80(-0.16)
Rank
#170→#116(+54 positions)
vs 7 days ago
Portfolio Context
Founder does not hold this stock.
Not in your portfolio.
Sector: Health Care
PEGY History — 90 days
Data: Yahoo Finance • Updated nightly 11 PM ET • For informational purposes only